BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 34467466)

  • 41. Frequency and relevance of elevated calcitonin levels in patients with neoplastic and nonneoplastic thyroid disease and in healthy subjects.
    Karanikas G; Moameni A; Poetzi C; Zettinig G; Kaserer K; Bieglmayer C; Niederle B; Dudczak R; Pirich C
    J Clin Endocrinol Metab; 2004 Feb; 89(2):515-9. PubMed ID: 14764755
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intraoperative high-dose calcium stimulation test in patients with sporadic medullary thyroid carcinoma is highly accurate in predicting lateral neck metastases.
    De Crea C; Raffaelli M; Milano V; Carrozza C; Zuppi C; Bellantone R; Lombardi CP
    Surgery; 2016 Jan; 159(1):70-6. PubMed ID: 26456123
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fine-needle aspiration cytology for medullary thyroid carcinoma: a single institutional experience in Japan.
    Suzuki A; Hirokawa M; Takada N; Higuchi M; Ito A; Yamao N; Hayashi T; Kuma S; Miyauchi A
    Endocr J; 2017 Nov; 64(11):1099-1104. PubMed ID: 28883261
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum Calcitonin-Negative Medullary Thyroid Carcinoma: A Case Series of 19 Patients in a Single Center.
    Kim SJ; Yun HJ; Shin SJ; Lee YS; Chang HS
    Front Endocrinol (Lausanne); 2021; 12():747704. PubMed ID: 34803914
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Thyroid venous catheterization in the early diagnosis of familial medullary thyroid carcinoma.
    Wells SA; Baylin SB; Johnsrude IS; Harrington DP; Mendelsohn G; Ontjes DJ; Cooper CW
    Ann Surg; 1982 Nov; 196(5):505-11. PubMed ID: 7125737
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center.
    Elisei R; Romei C; Renzini G; Bottici V; Cosci B; Molinaro E; Agate L; Cappagli V; Miccoli P; Berti P; Faviana P; Ugolini C; Basolo F; Vitti P; Pinchera A
    J Clin Endocrinol Metab; 2012 Feb; 97(2):426-35. PubMed ID: 22162466
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of two provocative tests for calcitonin in medullary thyroid carcinoma: omeprazole vs pentagastrin.
    Vitale G; Ciccarelli A; Caraglia M; Galderisi M; Rossi R; Del Prete S; Abbruzzese A; Lupoli G
    Clin Chem; 2002 Sep; 48(9):1505-10. PubMed ID: 12194927
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical performance of calcitonin and procalcitonin Elecsys
    Giovanella L; Fontana M; Keller F; Verburg FA; Ceriani L
    Clin Chem Lab Med; 2021 Mar; 59(4):743-747. PubMed ID: 33085633
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The value of 18F-DOPA PET/CT in patients with medullary thyroid carcinoma and increased calcitonin values.
    Golubić AT; Pasini Nemir E; Žuvić M; Mutvar A; Kusačić Kuna S; Despot M; Samardžić T; Huić D
    Nucl Med Commun; 2017 Jul; 38(7):636-641. PubMed ID: 28562377
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Basal Serum Calcitonin, After Calcium Stimulation, and in the Needle Washout of Patients with Thyroid Nodules and Mild or Moderate Basal Hypercalcitoninemia.
    Rosario PW; Calsolari MR
    Horm Metab Res; 2017 Feb; 49(2):129-134. PubMed ID: 28166595
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Can procalcitonin be useful for medullary thyroid cancer?
    Kaczka K; Mikosiński S; Fendler W; Jałocha-Kaczka A; Pomorski L
    Endokrynol Pol; 2010; 61(5):430-6. PubMed ID: 21049453
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Relevance of calcitonin cut-off in the follow-up of medullary thyroid carcinoma for conventional imaging and 18-fluorine-fluorodihydroxyphenylalanine PET.
    Sesti A; Mayerhoefer M; Weber M; Anner P; Wadsak W; Dudczak R; Haug A; Karanikas G
    Anticancer Res; 2014 Nov; 34(11):6647-54. PubMed ID: 25368270
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma.
    Pacini F; Fontanelli M; Fugazzola L; Elisei R; Romei C; Di Coscio G; Miccoli P; Pinchera A
    J Clin Endocrinol Metab; 1994 Apr; 78(4):826-9. PubMed ID: 8157706
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Early therapeutic management of patients genetically predisposed to medullary thyroid cancer].
    Murat A; Modigliani E; Conte-Devolx B; Rohmer V; Leclerc L; Guilhem I; Bigorgne JC; Boneu A; Maes B; Chabre O; Niccoli P; Schuffenecker I; Giraud S
    Ann Chir; 1998; 52(5):455-60. PubMed ID: 9752487
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Medullary thyroid carcinoma: relationship of method of diagnosis to pathologic staging.
    Wells SA; Baylin SB; Gann DS; Farrell RE; Dilley WG; Preissig SH; Linehan WM; Cooper CW
    Ann Surg; 1978 Sep; 188(3):377-83. PubMed ID: 686900
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Negative predictive value of procalcitonin in medullary thyroid carcinoma.
    Lim SK; Guéchot J; Vaubourdolle M
    Ann Biol Clin (Paris); 2016; 74(2):213-8. PubMed ID: 26806393
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Calcitonin measurement in wash-out fluid from fine needle aspiration of neck masses in patients with primary and metastatic medullary thyroid carcinoma.
    Boi F; Maurelli I; Pinna G; Atzeni F; Piga M; Lai ML; Mariotti S
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2115-8. PubMed ID: 17405835
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL).
    Bethel MA; Patel RA; Thompson VP; Merrill P; Reed SD; Li Y; Ahmadi S; Katona BG; Gustavson SM; Ohman P; Iqbal N; Gagel RF; Hernandez AF; Buse JB; Holman RR;
    Diabetes Care; 2019 Jun; 42(6):1075-1080. PubMed ID: 31010875
    [TBL] [Abstract][Full Text] [Related]  

  • 59. (18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma.
    Archier A; Heimburger C; Guerin C; Morange I; Palazzo FF; Henry JF; Schneegans O; Mundler O; Abdullah AE; Sebag F; Imperiale A; Taïeb D
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1027-33. PubMed ID: 26497699
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Urine calcitonin as a test for medullary thyroid cancer: a new screening procedure.
    Silva OL; Snider RH; Moore CF; Becker KL
    Ann Surg; 1979 Mar; 189(3):269-74. PubMed ID: 426557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.